N	Concordance
1	 receive either cytarabine/daunorubicin/etoposide (ADE) or cytarabine/daunorubi
2	xcessive toxicity, the duration of oral etoposide administration was reduced fro
3	mparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in 
4	     cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy for       
5	 J TI  - Experience with ifosfamide and etoposide combination chemotherapy in   
6	  whether the frequency was assessed at etoposide concentrations achieving equiv
7	onses to therapy. We have increased the etoposide dose to 100 mg/m2 in subsequen
8	 intravenous infusions of melphalan and etoposide for 3 days beginning at least 
9	     Thatcher N: Ifosfamide/carboplatin/etoposide (ICE) regimen in small cell   
10	ond mutation that confers resistance to etoposide-induced apoptosis in a genetic
11	ophosphamide IV over 1 hour followed by etoposide IV over 2 hours on day  0, the
12	s       prolonged (15 day) infusions of etoposide phosphate in small cell lung  
13	and 2 with  MESNA therapy.  Intravenous etoposide therapy is given over 1 hour o
14	 HCC which had been treated with either etoposide (VP-16) or doxorubicin. P-glyc